Pre-clinical models of GBM have shown NK cells to be effective in HLA class I-mediated tumor lysis (153); IL-2 activated NK cells' ability to kill GBM cells (154), and NK cells' effectiveness in preventing metastasis in the GBM xenograft mouse model have been reported (155). Here, IL2 is linked to glioblastoma.